Financial Performance - OnKure Therapeutics reported approximately $59.1 million in cash and cash equivalents as of December 31, 2025[6]. - Research and development (R&D) expenses for Q4 2025 were $10.7 million, a decrease of $3.6 million from $14.4 million in Q4 2024[6]. - General and administrative (G&A) expenses for Q4 2025 were $3.4 million, down from $4.3 million in Q4 2024, reflecting a decrease of $0.9 million[7]. - The net loss for Q4 2025 was $13.5 million, or $0.99 per share, compared to a net loss of $17.4 million, or $1.37 per share, in Q4 2024[8]. - Total operating expenses for the year ended December 31, 2025, were $62.95 million, compared to $54.39 million for the year ended December 31, 2024[19]. Clinical Trials and Research - OnKure has dosed a total of 71 patients in the PIKture-01 trial, with 38 in monotherapy and 33 in combination with fulvestrant[3]. - The company expects to report updated safety and clinical activity data from the PIKture-01 trial in March 2026[2]. - OnKure plans to announce its next-generation PI3Kα pan-mutant inhibitor candidate for HR+ metastatic breast cancer in March 2026[4]. - The company continues to enroll patients in the triplet expansion arm of the PIKture-01 trial, with 17 patients dosed in combination with fulvestrant and ribociclib[3]. - OnKure's strategic expansion into indications driven by PI3Kα biology aims to address a large and underserved patient population[5].
OnKure Therapeutics, Inc.(OKUR) - 2025 Q4 - Annual Results